InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2 |
YIQPUIGJQJDJOS-UHFFFAOYSA-N |
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3 |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
immunological adjuvant
A substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity.
anti-HIV agent
An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
C-X-C chemokine receptor type 4 antagonist
An antogonist that blocks C-X-C chemokine receptor type 4 (CXCR-4).
|
|
immunological adjuvant
A substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane)
|
plérixafor
|
WHO MedNet
|
plerixafor
|
WHO MedNet
|
plerixafor
|
WHO MedNet
|
plerixaforum
|
WHO MedNet
|
1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane)
|
IUPAC
|
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
|
ChEBI
|
AMD 3100
|
ChEBI
|
AMD-3100
|
DrugBank
|
AMD3100
|
DrugBank
|
JKL 169
|
ChemIDplus
|
JM3100
|
ChEBI
|
SDZ SID 791
|
ChemIDplus
|
110078-46-1
|
CAS Registry Number
|
ChemIDplus
|
17324009
|
PubMed citation
|
Europe PMC
|
18847313
|
PubMed citation
|
Europe PMC
|
24179472
|
PubMed citation
|
Europe PMC
|
26106388
|
PubMed citation
|
Europe PMC
|
26154069
|
PubMed citation
|
Europe PMC
|
26600122
|
PubMed citation
|
Europe PMC
|
27575003
|
PubMed citation
|
Europe PMC
|
28411174
|
PubMed citation
|
Europe PMC
|
29461034
|
PubMed citation
|
Europe PMC
|
30037618
|
PubMed citation
|
Europe PMC
|
30290049
|
PubMed citation
|
Europe PMC
|
30422351
|
PubMed citation
|
Europe PMC
|
30776910
|
PubMed citation
|
Europe PMC
|
7913308
|
PubMed citation
|
Europe PMC
|
|